{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:18:42Z","timestamp":1780481922118,"version":"3.54.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901101"],"award-info":[{"award-number":["81901101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) is a common subtype of mitochondrial encephalomyopathy. However, few studies have explored the relationship between biochemical markers and prognosis. This study aimed to explore the relationship between clinical and biochemical markers and prognosis of patients with MELAS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective single-center study. A total of 39 MELAS patients were followed for an average of 7.3\u2009\u00b1\u20094.7 (range 1\u201321\u2009years). All patients underwent detailed demographic registration, neurological examinations, biochemical and mitochondrial DNA analyses, muscle biopsy. Throughout the follow-up period, the modified Rankin Scale (mRS) scores, recurrent strokes rates, and mortality were tracked.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All patients initially presented with stroke-like episodes. Of the 39 subjects who were followed, 8 died, primarily due to acute stroke-like episodes and status epilepticus. Univariate analysis showed a higher risk of mortality in patients with severe lactate elevation compared to those with normal and mildly elevated levels (OR\u2009=\u20095.714, 95% CI 1.086\u201330.071, <jats:italic>p<\/jats:italic>\u2009=\u20090.040). While the absence of anemia was associated with a lower risk of death compared to those with anemia (OR\u2009=\u20090.175, 95% CI 0.033\u20130.921, <jats:italic>p<\/jats:italic>\u2009=\u20090.040). In multivariate analysis, severe lactate elevation (OR\u2009=\u20097.279, 95% CI 1.102\u201348.086, <jats:italic>p<\/jats:italic>\u2009=\u20090.039) and anemia (OR\u2009=\u20090.137, 95% CI 0.021\u20130.908, <jats:italic>p<\/jats:italic>\u2009=\u20090.039) were identified as independent predictors of mortality. MRS scores were categorized as follows: 41% of patients scored 0 to 2, 38.5% scored 3 to 5, and 20.5% had a score of 6 or had died. There was a positive correlation between lactic acid levels and MRS scores (r\u2009=\u20090.460, <jats:italic>p<\/jats:italic>\u2009=\u20090.003). In contrast, hemoglobin levels were negatively correlated with MRS scores (r\u2009=\u2009\u22120.375, <jats:italic>p<\/jats:italic>\u2009=\u20090.015). Furthermore, a positive correlation was observed between MRS scores and the frequency of stroke-like episodes (r\u2009=\u20090.280, <jats:italic>p<\/jats:italic>\u2009=\u20090.042).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study found that the majority of patients with MELAS had poor clinical outcomes. Anemia and significantly increased lactate levels were identified as indicators of poor prognosis in MELAS. Early intervention may lead to improvements in clinical outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1491283","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T05:10:37Z","timestamp":1733289037000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term prognostic factors and outcomes in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes: a clinical and biochemical marker analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Rui","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/archneurol.2008.526","article-title":"Protean phenotypic features of the A3243G mitochondrial DNA mutation","volume":"66","author":"Kaufmann","year":"2009","journal-title":"Arch Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nrneurol.2013.126","article-title":"The clinical maze of mitochondrial neurology","volume":"9","author":"DiMauro","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jns.2017.12.033","article-title":"Survival analysis of a cohort of Chinese patients with mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) based on clinical features","volume":"385","author":"Zhe","year":"2018","journal-title":"J Neurol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.bbagen.2011.03.015","article-title":"MELAS: a nationwide prospective cohort study of 96 patients in Japan","volume":"1820","author":"Shuichi","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"ref5","first-page":"255","article-title":"Prediction of long\u2010term prognosis by heteroplasmy levels of the m.3243A>G mutation in patients with themitochondrial encephalomyopathy, lactic acidosis and stroke\u2010like episodessyndrome","author":"Fayssoil","year":"2017"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/088307389400900102","article-title":"Topical review: mitochondrial myopathy, encephalopathy, lactic acidosis, and Strokelike episodes (MELAS): current concepts","volume":"9","author":"Hirano","year":"1994","journal-title":"Child Neurol Open"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1212\/01.WNL.0000033795.17156.00","article-title":"Diagnostic criteria for respiratory chain disorders in adults and children","volume":"59","author":"Bernier","year":"2002","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/gim.2014.177","article-title":"Diagnosis and management of mitochondrial disease: a consensus statement from the mitochondrial medicine society","volume":"17","author":"Sumit","year":"2014","journal-title":"Genet Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ana.22427","article-title":"Acute ischemic stroke in children versus young adults","volume":"70","author":"Sandra","year":"2011","journal-title":"Ann Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1212\/WNL.0b013e31823a0c7f","article-title":"Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype","volume":"77","author":"Kaufmann","year":"2011","journal-title":"Neurology"},{"key":"ref11","first-page":"1470","article-title":"A 3-year clinical follow-up of adult patients with 3243A>G in mitochondrial DNA","author":"Majamaa-Voltti","year":"2006"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jfma.2011.06.014","article-title":"Prognosis of symptomatic patients with the A3243G mutation of mitochondrial DNA","volume":"111","author":"Liu","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2015.06.004","article-title":"MELAS syndrome: clinical manifestations, pathogenesis, and treatment options","volume":"116","author":"Ayman","year":"2015","journal-title":"Mol Genet Metab"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/08990220.2020.1720636","article-title":"An analysis of the clinical and imaging features of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS)","volume":"37","author":"Hao","year":"2020","journal-title":"Somatosens Mot Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/brain\/awab353","article-title":"Forecasting stroke-like episodes and outcomes in mitochondrial disease","volume":"145","author":"Yi Shiau","year":"2021","journal-title":"Brain"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e136055","DOI":"10.1172\/JCI136055","article-title":"Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity","volume":"131","author":"Rohit","year":"2021","journal-title":"J Clin Invest"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e8262","DOI":"10.15252\/emmm.201708262","article-title":"mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease","volume":"10","author":"John","year":"2018","journal-title":"EMBO Mol Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1097\/MPH.0000000000002890","article-title":"Hematologic manifestations in primary mitochondrial diseases","volume":"46","author":"Arthavan","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/ncb3529","article-title":"The mitochondrial respiratory chain is essential for haematopoietic stem cell function","volume":"19","author":"Elena","year":"2017","journal-title":"Nat Cell Biol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s10545-017-0084-9","article-title":"The presence of anaemia negatively influences survival in patients with POLG disease","volume":"40","author":"Omar","year":"2017","journal-title":"J Inherit Metab Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.2169\/internalmedicine.51.7529","article-title":"Taurine ameliorates impaired the mitochondrial function and prevents stroke-like episodes in patients with MELAS","volume":"51","author":"Mitsue","year":"2012","journal-title":"Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.mito.2019.02.001","article-title":"Biomarkers and clinical rating scales for sodium pyruvate therapy in patients with mitochondrial disease","volume":"48","author":"Yasutoshi","year":"2019","journal-title":"Mitochondrion"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1007\/s00415-018-9057-7","article-title":"Therapeutic regimen of l-arginine for MELAS: 9-year, prospective, multicenter, clinical research","volume":"265","author":"Yasutoshi","year":"2018","journal-title":"J Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1182\/blood.2023022004","article-title":"Mitochondrial tRNA pseudouridylation governs erythropoiesis","volume":"144","author":"Bichen","year":"2024","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"fcaa222","DOI":"10.1093\/braincomms\/fcaa222","article-title":"Serum biomarkers in primary mitochondrial disorders","volume":"3","author":"Kristin","year":"2021","journal-title":"Brain Commun"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/ana.24506","article-title":"Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders","volume":"78","author":"Shuichi","year":"2015","journal-title":"Ann Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ymgme.2007.11.018","article-title":"The in-depth evaluation of suspected mitochondrial disease","volume":"94","author":"Richard","year":"2008","journal-title":"Mol Genet Metab"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1491283\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T05:10:41Z","timestamp":1733289041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1491283\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":27,"alternative-id":["10.3389\/fneur.2024.1491283"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1491283","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"article-number":"1491283"}}